Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: Outcomes from the CONKO-003 Trial

Journal of Clinical Oncology

Volumn 32, Issue 23, 2014, Pages 2423-2429

  Oettle, Helmut ^a,b   Riess, Hanno ^a   Stieler, Jens M ^a   Heil, Gerhard ^c   Schwaner, Ingo ^b   Seraphin, Jörg ^d   Görner, Martin ^e   Mölle, Matthias ^f   Greten, Tim F ^g   Lakner, Volker ^h   Bischoff, Sven ^a   Sinn, Marianne ^a   Dörken, Bernd ^a   Pelzer, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Clinical Research Center   (Germany)

^c Clinical Center   (Germany)

^d Clinical Center   (Germany)

^e Clinical Center   (Germany)

^f Center for Clinical Studies   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h Clinical Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GERMANY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE COURSE; DRUG RESISTANCE; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84905817411     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.6995     Document Type: Article

References (27)

1. Gounaris I, Zaki K, Corrie P: Options for the treatment of gemcitabine-resistant advanced pancreatic cancer. JOP 11:113-123, 2010
2. Todaka A, Fukutomi A, Boku N, et al: S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol 40:567-572, 2010
3. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997 (Pubitemid 27251144)
4. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007 (Pubitemid 46972777)
5. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
6. Von Hoff DD, Ervin T, Arena FP, et al: Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. N Engl J Med 369: 1691-1703, 2013
7. Pelzer U, Stieler J, Roll L, et al: Second-line therapy in refractory pancreatic cancer: Results of a phase II study. Onkologie 32:99-102, 2009
8. Kulke MH, Blaszkowsky LS, Ryan DP, et al: Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25:4787- 4792, 2007
9. Tsavaris N, Kosmas C, Skopelitis H, et al: Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs 23:369-375, 2005 (Pubitemid 40980360)
10. Petrelli F, Borgonovo K, Ghilardi M, et al: What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies. Rev Recent Clin Trials 5:43-56, 2010
11. Yoo C, Hwang JY, Kim JE, et al: A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 101:1658-1663, 2009
12. Rahma OE, Duffy A, Liewehr DJ, et al: Second-line treatment in advanced pancreatic cancer: A comprehensive analysis of published clinical trials. Ann Oncol 24:1972-1979, 2013
13. Pelzer U, Schwaner I, Stieler J, et al: Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group. Eur J Cancer 47:1676-1681, 2011
14. Almhanna K, Kim R: Second-line therapy for gemcitabine-refractory pancreatic cancer: Is there a standard? Oncology (Williston Park) 22:1176-1183, 2008; discussion 1190, 1192, 1196
15. Novarino A, Satolli MA, Chiappino I, et al: Oxaliplatin, 5-fluorouracil, and leucovorin as secondline treatment for advanced pancreatic cancer. Am J Clin Oncol 32:44-48, 2009
16. Androulakis N, Syrigos K, Polyzos A, et al: Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: A multicenter phase II study. Cancer Invest 23:9-12, 2005 (Pubitemid 40344194)
17. Yi SY, Park YS, Kim HS, et al: Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol 63:1141-1145, 2009
18. Cereda S, Reni M: Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. J Chemother 20:509-512, 2008
19. Oettle H, Arnold D, Esser M, et al: Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11:635-638, 2000
20. Renouf DJ, Tang PA, Major P, et al: A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest New Drugs 30:1203-1207, 2012
21. Boeck S, Weigang-Köhler K, Fuchs M, et al: Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: A multicenter phase II trial. Ann Oncol 18:745-751, 2007 (Pubitemid 46523280)
22. Xiong HQ, Varadhachary GR, Blais JC, et al: Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113:2046- 2052, 2008
23. Demols A, Peeters M, Polus M, et al: Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: A phase II study. Br J Cancer 94:481-485, 2006 (Pubitemid 43289750)
24. O'Reilly EM, Niedzwiecki D, Hall M, et al: A cancer and leukemia group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist 15:1310-1319, 2010
25. Astsaturov IA, Meropol NJ, Alpaugh RK, et al: Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. Am J Clin Oncol 34:70- 75, 2011
26. Wolpin BM, Hezel AF, Abrams T, et al: OralmTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 27:193-198, 2009
27. Bodoky G, Timcheva C, Spigel DR, et al: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 30:1216-1223, 2012